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Renal aging, by itself, is associated with alterations in renal
morphology and a decline in renal function, which is
accelerated and/or accentuated by diseases such as diabetes
mellitus and hypertension. The aging-related renal
insufficiency has important implications with regards to body
homeostasis, drug toxicity, and renal transplantation. An
understanding of renal aging and its distinction from renal
insufficiency secondary to diseases is essential for
individualized care of the elderly. Toward this end,
investigations are underway to elucidate the molecular
mechanisms of renal aging. This review summarizes the
structural and functional changes of the aging kidney and
highlights the advances made in our understanding of the
renal aging process.
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Improvements in sanitation and health care have led to a
worldwide increase in human life expectancies. Simulta-
neously, lower growth rates in the developed world have
contributed to the relative increase in the elderly population.
Thus, by 2030, there will be 71 million Americans aged 65
years or older accounting for approximately 20% of the US
population.1 Similarly, in the European Union, adults aged 60
years and more comprise 21% of the population and are
projected to increase to 27% by 2022 and to 33% by 2050.2
Similarly, there are 143 million people aged 60 years or older
in China currently accounting for 11% of its population and
this is projected to increase to an alarming 374 million by
2040 comprising 24.8% of the Chinese population.3 This
growing geriatric population has medical, social, and
economic impacts that need to be addressed and studied.
An important geriatric medical issue with socioeconomic
ramifications is that of aging-associated renal diseases.4 Accord-
ing to the US Renal Data System, during 1995–2005, the adjusted
point prevalence rates per million population of reported end-
stage renal disease increased from 70.5 to 82.1 (16% increase) in
the age group 0–19 years, from 730.6 to 858.2 (17% increase) in
the age group 20–44 years, from 2333.3 to 3150.4 (35% increase)
in the age group 45–64 years, from 3627.5 to 5500.6 (51%
increase) in the age group 65–74 years, and from 2762.4 to
4795.8 (73% increase) in the age group 75þ years.5 The aging
kidney may be affected by many diseases (Table 1), none of
which is specific to the elderly, although certain disorders may
have an increased prevalence in the geriatric population (for
example, renal disease secondary to type 2 diabetes mellitus,
hypertension, and amyloidosis).6 Despite the widespread use of
the term ‘arterionephrosclerosis of aging’ by pathologists and
clinicians to describe the pathological changes observed in the
senescent kidney, it is not a well-defined entity because no
specific morphological findings are pathognomonical for the
aging kidney and, as such, aging kidney (arterionephrosclerosis
of aging) is a diagnosis of exclusion. Therefore, renal pathologists
and nephrologists need to rule out glomerular, tubulointerstitial,
and vascular diseases before ascribing the morphological and
functional changes to aging-related decline in renal function.
The latter is the focus of this review.
FUNCTIONAL CHANGES OF THE AGING KIDNEY
Numerous reviews have addressed the functional changes
associated with renal senescence.7,8 Although they are all
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interrelated, it is convenient to consider glomerular, tubular,
and endocrine functions individually.
Glomerular function
It is believed that after the age of about 30 years, the
glomerular filtration rate (GFR) begins to decline at an
average rate of 1 ml per year, resulting in an inulin clearance
of 65 ml/min at the age of 90 years.9 However, this dogma has
been challenged. In the Baltimore longitudinal study of aging
among 254 ‘normal’ subjects, although the mean decline in
creatinine clearance (CrCl) was 0.75 ml/min/year, 36% of the
subjects showed no aging-related decrease in CrCl, and a few
of these subjects actually showed an increase in their CrCl.10
This variability suggests that factors other than aging may be
responsible for apparent reduction in renal function. For
instance, increase in blood pressure (even still within the
normotensive range) or low high-density lipoprotein choles-
terol is associated with accelerated age-related loss of renal
function.10,11 Conversely, in Bronx longitudinal aging study
comprising 141 very elderly subjects, there was a small but
significant decline in blood urea nitrogen and serum
creatinine at 3 years, which persisted, although at a lower
rate, at 6 years. This was associated with slight decrease in
diastolic blood pressure.12,13 A similar pattern of decreasing
blood urea nitrogen and creatinine was seen in the 31
subjects who entered the study with mild azotemia. The
authors conclude that blood urea nitrogen and serum
creatinine do not necessarily increase with time in the old
individuals, even in those with mild azotemia. They further
noted that although renal function in the elderly does not
improve with time, it may stabilize with satisfactory blood
pressure control. Thus the decline in renal function with age,
per se, may not be clinically significant unless it is
superimposed by acute/chronic illnesses further compromis-
ing the renal function/renal reserve. As noted above,
controversy persists as to whether the decline in GFR is an
appropriate consequence of normal aging process or the
result of the associated comorbidities.6,10,11
Creatinine clearance is influenced by the nutritional
status, protein intake, and muscle mass and is therefore not
an accurate measure of the GFR in the elderly.14 The
creatinine production and the urinary creatinine output
gradually decline in proportion to the aging-related decrease
in muscle mass and body weight. Thus, plasma creatinine
does not increase with increasing age, despite the aging-
related reduction in CrCl.15 The true GFR, measured by
inulin clearance, in the ‘healthy’ elderly subjects, although
significantly lower than in the young, remains within the
normal range and is underestimated by CrCl and even more
so when calculated by the Cockroft–Gault (CG) forrmula.16,17
The Modification of Diet in Renal Disease (MDRD) Study
Group formula for calculating GFR is considered more
accurate than the CG formula.18,19 Notably, neither CG nor
MDRD equation has been validated in the population older
than 70 years. In a study involving 100 individuals aged
65–111 years, GFR values calculated with the MDRD formula
were much higher than that obtained with the CG equation.
Additionally, the difference in GFR values between MDRD
and CG increased dramatically with aging. Moreover, no
correlation was observed between predicted values obtained
with the two methods. Thus, the precision and accuracy
of these formulas in estimating GFR in the elderly
remain dubious.20 Another study showed more than 60%
Table 1 | Diseases that commonly affect the aging kidney
Systemic diseases
Hypertension
Diabetes mellitus
Dyslipidemia
Atherosclerosis
Atheroemboli
Myeloma cast nephropathy
Amyloidosis
Light-chain deposition disease
Vasculitides
Glomerular diseases
Membranous glomerulopathy
Mesangial proliferative GN (including IgA nephropathy)
Pauci-immune crescentic GN
Anti-GBM disease
Minimal change disease
Focal segmental glomerulosclerosis
Acute renal failure
Hypovolemic and cardiovascular shock
Septic shock
Nephrotoxic injury
Nonsteroidal anti-inflammatory agents
Antibiotics (penicillins, cephalosporins, sulfonamides, rifampin,
ciprofloxacin)
Diuretics (furosemide, potassium-sparing diuretics)
Contrast media
Cancer chemotherapy
Allopurinol
Cimetidine
Captopril
Interstitial nephritis
Urinary tract infection
Renal stones
Obstructive uropathy
Benign causes
Nodular hyperplasia of prostate
Neurogenic bladder
Renal stones
Obstructive pyelonephritis/papillary necrosis
Urethral stricture
Malignant causes
Prostate cancer
Bladder cancer
Pelvic tumors
Colonic tumors
Retroperitoneal tumors
Renal tumors
Primary
Metastatic
Simple renal cysts
GBM, glomerular basement membrane; GN, glomerulonephritis.
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discordance in GFR estimation by the two equations in
individuals over 65 years. MDRD equation generally yielded
higher estimates of GFR than CG equation.21 This has
important implications, especially when calculating drug
dosages in the elderly. Overestimation of GFR can inadver-
tently result in unexpected drug toxicity. It was thus
recommended that the CG equation should be used in
preference to MDRD equation to estimate GFR for drug
dosage calculations in the elderly.22 Serum cystatin C
measurement, especially when compared with reference
values adjusted for age, may be a promising index of renal
insufficiency in the elderly.23
Under normal conditions, renal vasodilation leads to a
significant increase in the renal blood flow and GFR,
representing renal hemodynamic and functional reserves.
The increase in the renal plasma flow (RPF) and GFR in
response to maximum renal vasodilation induced by
concurrent infusion of amino acids and dopamine is
markedly reduced in healthy elderly individuals.24,25 This
phenomenon points to structural, rather than functional,
changes such as imbalance between vasodilatory and
vasoconstrictive influences in the aging kidneys. In a recent
study, Ahmed et al.26 have shown that the reduction in RPF
induced by intravenous administration of the nitric oxide
(NO) synthase (NOS) inhibitor, L-NAME (nitro-L-arginine
methyl ester), increased markedly with aging in men but not
women, indicating that the renal vasculature of men becomes
more dependent on NO with age compared with that of
women. Similarly, increasing plasma levels of endogenous
NOS inhibitor, ADMA (asymmetric dimethylarginine), and
associated NO deficiency are shown to contribute to the
aging-related decline in RPF.27 In addition, systemic ADMA
infusion in healthy people significantly decreased effective
RPF and increased renovascular resistance and mean arterial
blood pressure.28 The reduction in renal hemodynamic and
functional reserves can compromise renal adaptation to acute
ischemia and as such can heighten susceptibility to acute
renal injury in the geriatric population.
Tubular function
Aging-related alteration in renal tubular function manifests
in multiple ways. For instance, the reduction in urinary
sodium excretion in response to dietary sodium chloride
deprivation is significantly slowed down in the elderly as
compared with young individuals.29 This phenomenon
accounts for the increased susceptibility of the elderly to
volume depletion. On the other hand, under steady-state
condition, the elderly as well as the young can maintain
sodium balance. For instance, on a diet containing 4000 mg
of sodium, there were no significant differences in the mean
24-h urinary sodium excretion and fractional excretion of
sodium between the healthy young and the healthy elderly,
the hypertensive elderly, and the elderly with compensated
mild-to-moderate heart failure. Compared with the healthy
young subjects, the mean lithium clearance, an indicator of
proximal tubular function, was significantly lower in all three
groups of elderly subjects. Accordingly, the fractional
proximal sodium reabsorption was significantly higher in
the elderly, but was offset by the lower distal fractional
reabsorption of sodium.30 The handling of potassium is
negatively affected by aging, explaining the predisposition of
the elderly to developing drug-induced hyperkalemia. The
urine potassium is derived from active transtubular transport
in the distal nephron and collecting duct, which is linked to
the reabsorption of sodium across the aldosterone-modu-
lated Na-K ATPase transporters. Thus, impaired potassium
secretion (and the corresponding impaired sodium reabsorp-
tion) may occur because of tubular atrophy or tubulointer-
stitial scarring due to previous pyelonephritis or ongoing
glomerulosclerosis; hyporeninemic or normoreninemic hy-
poaldosteronism; and decreased water and sodium delivery
to the distal nephron due to dehydration and reduced
intravascular volume.31 The ability of the kidney to both
maximally concentrate and dilute the urine also diminishes
with age,32,33 explaining the higher rate of nocturia34 and the
predisposition to dehydration and hypernatremia as well as
to hyponatremia if excess fluid is administered.35
One of the major medical implications of aging is the
heightened susceptibility to drug toxicity in the elderly
population.36 This, in part, is due to the altered drug
pharmacokinetics that stems from a decline in the functional
capacity of the kidney and most, if not all, other organs, as
well as altered body composition (reduced water and
increased fat), which accompanies advanced age. In this
context, the reduction in excretory capacity of the kidney
and, to a lesser extent, the decline in the hepatic metabolism
contribute to the altered pharmacokinetics of many drugs in
the elderly population. In addition, aging adversely affects
pharmacodynamics of many drugs by modulating the
sensitivity and physiological response to their actions
irrespective of the change in their disposition. For instance,
in the elderly, the central nervous system is highly vulnerable
to drugs such as benzodiazepines, opioids, and psychotropic
agents. On the other hand, the diminished sensitivity of the
cardiovascular system to beta-adrenergic stimuli predisposes
the elderly individuals who are treated with antihypertensive
medications to orthostatic hypotension. The combination of
altered pharmacodynamics and pharmacokinetics in the
elderly patients with comorbid conditions requiring multiple
medications presents an increasingly common and complex
problem. Therefore, it is prudent to initiate therapy at the
drug dosage with lowest effect and increase the dose slowly, if
needed, in the older patient.
Endocrine function
The increase in the prevalence of anemia with decreasing
renal function37 may be related to the reduced erythropoietin
(EPO) production by the kidney.38 Although the serum EPO
levels increase with age in healthy subjects, perhaps as a
compensatory response to age-related subclinical blood loss,
increased erythrocyte turnover, or increased EPO resis-
tance,39 the levels are unexpectedly lower in the anemic
712 Kidney International (2008) 74, 710–720
r e v i e w XJ Zhou et al.: The aging kidney
elderly compared with the anemic young, suggesting a
blunted response to low hemoglobin.40–42 Elderly women
with osteoporosis and low CrCl (o60 ml/min) have lower
calcium absorption, lower serum 1,25-dihydroxyvitamin D,
and normal serum 25-hydroxyvitamin D, suggesting a
diminished conversion of 25-hydroxyvitamin D to 1,25-
dihydroxyvitamin D by the aging kidney.43 A CrCl of less
than 65 ml/min is reported to be an independent risk factor
for falls and associated fractures in the elderly with
osteoporosis,44 and calcitriol therapy reduced the number
of falls by 50%, possibly related to an increase in serum 1,25-
dihydroxyvitamin D in addition to an upregulation of
vitamin D receptors in the muscle and an improvement in
muscle strength.43
Kidney is the major site of insulin clearance from the
systemic circulation,45 removing approximately 50% of
insulin in the peripheral circulation. Insulin clearance by
the kidney is accomplished by glomerular filtration and
proximal tubular uptake and degradation. Consequently, the
decline in renal function in the elderly leads to reduced
insulin clearance. This is, in part, offset by diminished
glucose tolerance, which appears to be due to defective
insulin secretion and action with aging. It has been suggested
that the impaired insulin secretion of aging rats may not be
due to old age per se, but rather due to associated chronic
renal insufficiency and excess of parathyroid hormone.46 A
recent study showed that insulin action, measured with either
the meal or the intravenous glucose minimal models, was
lower in the elderly than in the young participants, suggesting
increased peripheral resistance to insulin in the elderly.47
Insulin secretion was also impaired in the elderly individuals,
indicating decreased b-cell secretory reserve. Thus, whereas
total body insulin clearance is lower in the elderly than in the
young subjects, geriatric patients are at a higher risk of
glucose intolerance.
The kidneys also play a central role in sympathetic
regulation. Sympathetic nervous system activity is elevated in
patients with chronic kidney disease48 and persists after
transplantation.49 It is possible that chronic activation of the
sympathetic nervous system contributes to arterial stiffening
in these patients with generally advanced arterial disease.
Similar arterial stiffening is observed in the elderly and is
associated with declining renal function. It is plausible that
increased sympathetic tone caused by declining GFR and
other factors contributes to vascular changes in the elderly.
STRUCTURAL CHANGES OF THE AGING KIDNEY
The gross appearance of granularity and pitting of the
external surface of aging kidney is secondary to the under-
lying arterial disease, which leads to small regions of the
outer renal cortex to undergo global glomerulosclerosis,
tubular atrophy, and interstitial fibrosis (Figure 1). These
features are best correlated with aging-related intimal fibrosis
of the interlobular arteries (arterial sclerosis), a change that
may be accelerated by hypertension and diabetes mellitus.7,50,51
Arterial intimal fibrosis may be associated with medial
thinning and is found uniformly in the older kidneys with or
without underlying cardiovascular disease. The regional
heterogeneity of the intimal thickening may account for the
regional heterogeneity of the ischemic nephrons. The intimal
hyperplasia in the interlobular arteries may allow for the
transmission of the pulse wave abnormally into the smaller
distal branches leading to arteriolar hyaline changes, which
may then accelerate the proximal intimal fibrosis.52–55 The
aging kidney also contains a high percentage of afferent and
efferent arterioles that communicate directly with each other
(‘aglomerular arterioles’) because of loss of their glomeruli,
particularly in the juxtamedullary location.51
The average kidney weight progressively declines after the
fifth decade of life, with the renal cortex being affected more
than the medulla.8,50 Consistent with the decrease in kidney
weight and thinning of the cortical ribbon with increasing
age, the glomeruli decrease in number with increase in
age.56–58 In addition, the percentage of glomeruli showing
global glomerulosclerosis increases with age, and there are
direct correlations between the number/percentage of
globally sclerotic glomeruli and increasing age as well as
between the number/percentage of globally sclerotic glomer-
uli and intrarenal arterial disease, particularly the outer
cortical arterial disease.59 Up to 10% of the glomeruli may be
globally sclerotic in ‘normal’ subjects younger than 40 years.60
It has been suggested that ‘pathological’ glomerulosclerosis
should be seriously considered when the number of globally
sclerosed glomeruli exceeds the number calculated by the
formula: (patient’s age/2)10 (see ref. 61). Equally important
is the morphological evaluation of the globally sclerosed
glomeruli. Thus, an infiltrative process such as amyloidosis or
diabetes mellitus should be considered if a globally sclerosed
glomerulus appears larger than usual. The diseases of renal
arterial system should be excluded if an early-sclerosed
glomerulus displays shrinkage of the glomerular tuft,
wrinkling and thickening of the glomerular basement
membrane, and collagen deposition internal to Bowman’s
capsule near the vascular hilum.8 Sclerosed glomeruli with
breaks in the glomerular basement membrane may be a
Figure 1 | The aging kidney. Two glomeruli show solidified
global glomerulosclerosis. The nonsclerotic glomerulus displays
ischemic changes. There are also moderate tubular atrophy and
interstitial fibrosis. The arterioles reveal significant hyalinosis
(Periodic acid-Schiff stain;  200).
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sequela of severe glomerular inflammation and crescent
formation and should alert one to the possibility of
underlying IgA nephropathy, antineutrophil cytoplasmic
antibody-associated vasculitis, or lupus nephritis, among
others.50 In addition, aging human kidney is associated with
mesangial matrix expansion and thickening of the glomerular
basement membrane, although not all agree with these
findings.50 These changes are nonspecific and may be seen in
hypertension, diabetes, and many other renal disorders.
Similarly, tubular atrophy and interstitial fibrosis may be
aging-related or may occur due to chronic inflammation or
vascular disease.62 As EPO and 1,25-dihydroxy vitamin D are
produced by tubular or peritubular cells, tubulointerstitial
injury may, in part, contribute to EPO and vitamin D
deficiency seen in the elderly. The distal renal tubules develop
diverticula that increase in number with advancing age. The
diverticula in distal and collecting tubules may be precursors
of the simple renal cysts that are seen in half of the subjects
older than 40 years63,64 and may promote bacterial growth
and contribute to the frequent renal infections in the elderly.
PATHOGENESIS OF RENAL AGING
As described above, the major histological features of renal
aging are glomerulosclerosis, tubular atrophy, interstitial
fibrosis, and arterial intimal fibrosis. Although kidneys of the
elderly are affected by diseases like hypertension, diabetes
mellitus, and sporadic insults such as infections and drug
injuries, it appears that renal aging occurs in the absence of
systemic or local diseases, which can themselves accelerate the
‘natural’ process of aging. The pathogenesis of aging-
associated global glomerulosclerosis is likely multifactorial.
Dysautoregulation of the afferent and efferent arterioles of
the glomerulus may lead to increased glomerular plasma
flow, increased glomerular intracapillary pressures, and
subsequent ‘hyperperfusion’ glomerular injury with accumu-
lation of mesangial matrix.65,66 The vascular adaptations to
functional or structural nephron loss may help preserve the
GFR by producing hyperperfusion and hyperfiltration in the
surviving functional nephrons. This local glomerular hyper-
tension and hypertrophy may lead to cytokine-mediated
mesangial matrix expansion and eventual glomerulosclerosis.
Such hyperperfusion-induced glomerular injury is observed
with oligomeganephronia, diabetic nephropathy, morbid
obesity, and reflux nephropathy. It has been suggested that
the aging-associated arterial intimal fibrosis produces ische-
mia in the aging kidneys that first causes cortical glomerulo-
sclerosis and consequent juxtamedullary glomerular
hypertrophy, followed by juxtamedullary glomerulosclero-
sis.57 However, another study noted that the superficial
cortical glomeruli were 20% larger than the juxtamedullary
glomeruli in 12 adult males aged 51–69 years, suggesting that
the loss of glomeruli in the superficial cortex might shift
perfusion to adjacent functional glomeruli in the superficial
cortex and promote their enlargement.67 The tubulointer-
stitial changes also could be secondary to the aging-related
arterial changes and consequent hypoxia/ischemia in both
cortex and medulla. This is suggested by the upregulation, in
the aging rat kidney, of hypoxia-induced genes such as
hypoxia-inducible factor, vascular endothelial growth factor,
glucose transporter-1, and EPO.68 Similarly, the aging-
associated deposition of collagen in the rat kidney correlates
with an upregulation of the gene for collagen-1 and a
downregulation of the gene for matrix metalloproteinase-1.69
As described below, advanced glycosylation end products
(AGEs) and their receptor play a role in the aging process.
They may promote nuclear factor-kB activation and expres-
sion of inflammatory genes in the aging kidney.70,71 Based on
their observations in the kidneys of human tissue inhibitor of
metalloproteinase-1 transgenic mice, a group of investigators
have suggested that tissue inhibitor of metalloproteinase-1
could promote aging-related renal fibrosis, at least partly,
through inflammation by upregulation of intercellular
adhesion moleculer-1 and consequent upregulation of
transforming growth factor-b1.72 The latter is a fibrosis-
promoting cytokine implicated in aging-associated renal
fibrosis.73
Recently, considerable attention has been paid to the role
of arterial aging or arteriosclerosis in the pathogenesis of
senescent changes observed in the kidney and other organs. It
has been observed that with age, structural fatigue and
fracture leads to dilatation and stiffening of elastic
arteries.74,75 Arterial stiffness, in turn, increases pulse wave
velocity74,76 and thereby transmission of pulsatile energy to
fragile microvessels causing damage and injury in various
organs.77–80 Systemic microvascular disease may be associated
with progressive renal dysfunction in the elderly population.
This viewpoint was substantiated by findings of the
Cardiovascular Health Study, a prospective, multicenter,
cohort study initiated in 1989 to examine cardiovascular
risk factors, morbidity, and mortality in elderly Americans.81
The study showed that retinal microvascular abnormalities
were significantly associated with deterioration of renal
function, independent of the associated diabetes or hyperten-
sion. These observations suggest that renal abnormalities may
represent one manifestation of ongoing systemic microvas-
cular damage. Further studies have shown that measures of
large artery stiffness are closely related to markers of renal
microvascular injury including albuminuria, independent
of conventional brachial systolic and diastolic pressure
values.77–80 In fact, therapeutic interventions aimed at
reducing the ill effects of arterial stiffness by lowering the
magnitude and frequency of the stretch cycles (to minimize
fatigue and fracture of medial elastin in the aorta) can reverse
or delay progression of cerebral and renal damage. These
maneuvers entail a reduction in early wave reflection,
through regular exercise, and use of drugs (angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers,
calcium channel blockers, nitrates) that relax smooth muscles
in large and small conduit arteries throughout the body and
cause arterial dilation.80,82–84
The molecular basis of the phenomenon of renal aging is
under active investigation. In general, the theories of cellular
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senescence include genomic instability and telomere loss,
oxidative damage, genetic programming, and cell death.85
Here, we review some of the promising results from the
investigations directed specifically at renal aging (Figure 2).
Telomeres are DNA–protein complexes, located at the ends
of chromosomes. Telomeres protect the chromosomes from
fusing with each other. The enzyme telomerase synthesizes
the telomeric DNA, which are repeats of the sequence
TTAGGG. Most somatic cells do not synthesize telomerase,
and therefore telomeres shorten with each cell division.
Ultimately, these somatic cells are left with chromosomes that
have critically shortened telomeres. The cellular machinery
senses the critically short telomeres as DNA-strand breaks,
which leads to the activation of p53 and p16 and induction of
cell-cycle arrest and replicative senescence.86,87 Telomeres
shorten with increasing age in the kidney, more rapidly in the
renal cortex, where 0.24–0.25% telomere shortening occurs
annually.88
Cumulative oxidative stress is believed to play a major role
in the process of cellular aging. The increase in oxidative
stress and lipid peroxidation in the aging kidney correlates
with an increase in the AGEs and their receptors that can
cross-link adjacent proteins. In addition, the AGE-R1, the
receptor protective against AGE-mediated injury, is down-
regulated with aging.70,71 Along with reactive oxygen species
that can activate ubiquitin-proteasome, AGEs may degrade
hypoxia-inducible factor-1a and limit the capacity of the
aging cells to form hypoxia-inducible factor-1-DNA–hypoxia-
responsive recognition element complexes.3,89,90 The conse-
quent decrease in the ability of the renal cells to respond to
hypoxia could explain the previously mentioned attenuated
anemia-induced secretion of EPO and the decreased hypoxia-
induced production of vascular endothelial growth factor
leading to reduced angiogenesis.90 In a rat model, renal aging
was associated with a 60% reduction in the GFR, a threefold
increase in renal F2 isoprostanes (markers of oxidative stress),
and increased oxidant-sensitive heme oxygenase, AGEs, and
AGE receptors. Pertinently, a diet rich in the antioxidant
vitamin E attenuated the aging-related increased expression
of heme oxygenase and AGE receptors, suppressed the
production of F2 isoprostanes, and increased the GFR by
50% (see ref. 91). Oxidative stress has also been shown to
reduce telomere length.92 In cultured rabbit proximal tubular
epithelial cells, AGEs and even the early-glycosylation end
products (Amadori products) directly inhibited NOS activity,
and furthermore, AGEs quenched the released nitric oxide
(NO).93 By immunohistochemistry, aging rat kidneys
demonstrated a reduction of endothelial NOS (eNOS) in
the peritubular capillaries and the appearance of immuno-
detectable eNOS in the renal tubular epithelial cells and
infiltrating mononuclear cells in areas of tubulointerstitial
injury. These observations suggest that the aging-related renal
tubulointerstitial fibrosis may be secondary to the ischemia
associated with peritubular capillary injury and altered eNOS
expression.94 In addition, an aging-related decline in the
abundance of renal cortical neuronal NOS has been reported
in male Sprague–Dawley rats. The female rat, which is
protected from the aging-dependent renal damage, demon-
strates maintained levels of renal cortical eNOS and neuronal
NOS levels.95 This may be related to the stimulatory effects of
estrogen on the synthesis of eNOS and neuronal NOS.96
The renin–angiotensin system, through its effects on the
angiotensin receptor AT1, may induce the synthesis of
reactive oxygen species and transforming growth factor-b1
that produce fibrosis. Indeed, angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers ameliorated the
aging-related renal injury in rats as shown by a decline in
glomerular mesangial expansion and sclerosis, tubular
Genetic factors
Telomere shortening and replicative senescence
Oxidative stress
Aging
Diet
Infections and toxins
Diabetes mellitus
Hypertension
Arterial sclerosis
Hypoxia/Ischemia
Glomerular sclerosis
Tubular atrophy
Interstitial fibrosis
Renal insufficiency
Figure 2 | Proposed pathogenesis of renal aging and
associated renal injury. The pathogenesis of renal aging with its
associated structural and functional changes is not clearly
understood, mainly because of the difficulty in parsing the effect
of ‘natural aging’ and the cumulative effects of toxins and
diseases that may injure the kidney over the period of its life.
Replicative senescence and oxidative stress are the major factors
identified in the process of natural renal aging. These factors as
well as renal diseases and toxins ultimately lead to changes in
renal arterial system, the most important of which is renal arterial
sclerosis. It is suggested that the hypoxic/ischemic milieu created
by this arteriopathy produces the familiar aging-related renal
morphological changes of glomerular sclerosis, tubular atrophy,
and interstitial fibrosis. The subsequent functional insufficiency
drives the feedback to renin–angiotensin–aldosterone system to
produce hypertension, which then creates a cycle of further
arterial and arteriolar damage and renal ischemia. This simplistic
schema is complicated by factors such as gender, nitric oxide
synthesis and inhibition, renin–angiotensin system, dietary factors
(that is, salt load and caloric restriction), and the effect of
aging-associated genes such as klotho.
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atrophy, interstitial fibrosis, and mononuclear infiltration.97
This effect of angiotensin-converting enzyme inhibitors may
be mediated by their positive modulation of the aging-related
dysfunction in the mitochondria, the organelles involved in
energy metabolism, and reactive oxygen species produc-
tion.98 In addition, it has been shown that AT1 blockade
(losartan) prevented renal injuries in aged spontaneously
hypertensive rats by enhancing NO bioavailability and
ameliorating oxidative stress.99
A reduced expression of the anti-aging gene Klotho leads
to the development of an aging-like syndrome in mice,
whereas an overexpression of the Klotho protein leads to a
suppression of the aging-related organ degeneration, with an
elongation of the lifespan in mice. The Klotho protein is a
hormone that mediates its cellular effect by binding to a cell-
surface receptor and repressing the intracellular signals of
insulin and insulin-like growth factor 1.100,101 The anti-aging
effect of the Klotho-induced inhibition of insulin/insulin-like
growth factor 1 signaling appears to be associated with an
increased resistance to oxidative stress. Thus, the Klotho
protein induces the expression of the antioxidant enzyme,
manganese superoxide dismutase, which facilitates neutrali-
zation of reactive oxygen species, thereby conferring protec-
tion against oxidative stress.102 On the other hand, hydrogen
peroxide-induced oxidative stress led to a reduced expression
of Klotho in a murine inner medullary collecting duct
(mIMCD3) cell line.103 Angiotensin II can downregulate
renal expression of Klotho, an effect attenuated by iron
chelation and free radical scavenging in a rat model.104
Klotho may also be involved in vitamin D, calcium, and
phosphate metabolism through its proposed enzymatic b-
glucuronidase action on steroid b-glucuronides and the
calcium-channel transient receptor potential vallinoid-5.
Klotho may also be an essential cofactor for the stimulation
of fibroblast growth factor receptor by fibroblast growth
factor-23.105,106 Klotho is highly expressed in the human
kidney, where it colocalizes with transient receptor potential
vallinoid-5 in the distal renal tubular cells.107 Klotho gene
polymorphisms have been associated with bone mineral
density in women108,109 and with decreased longevity.110 A
homozygous missense mutation in the Klotho gene was
recently reported in a 13-year-old girl with severe tumoral
calcinosis with dural and carotid artery calcifications.111
Global gene expression by cDNA microarray analyses have
identified more than 500 genes differentially expressed
among human kidney samples from young (8 weeks to 8
years), adult (31–46 years), and old (71–88 years) subjects.112
Not surprisingly, the genes that showed declining expression
in the old kidneys included those associated with metabolic
processes like respiratory electron transport chain; glucose
and lipid metabolism; and protein, amino acid, and
nucleotide turnover. Other aging-related changes included
altered expression of the cytoskeletal genes. There were also
aging-associated increased expressions of the genes associated
with extracellular matrix synthesis and turnover and of
the genes encoding immune response and inflammatory
mediators. On the other hand, the older kidneys showed
reduced expressions of the genes associated with collagen
catabolism, as well as of the genes encoding glutathione-
related enzymes and the transporters involved in tubular
transport of electrolytes, ions, glucose, amino acids, and
organic acids. It should be noted that most of the data
addressing molecular mechanisms of senescence comes from
animal studies. Given the interspecies differences, caution
should be exercised in extrapolating these findings to humans.
CALORIC RESTRICTION AND RENAL AGING
The increase in net caloric intake and a sedentary lifestyle has
brought upon mankind an epidemic of obesity. Improved
eating habits and lifestyle modifications are, therefore,
essential to reverse this trend. In addition to this obvious
association, caloric restriction has long been studied as a
means of achieving longer life spans. More than 80 years ago,
McCay et al.113 demonstrated an extension in the maximum
lifespan of rats raised on a life-long calorie-restriction diet
without malnutrition. Other studies have confirmed these
results and have also shown that the long-term caloric
restriction slows the aging-related decline in physiological
processes and slows the development of aging-related
diseases.114,115 Although life-long caloric restriction studies
are not available in humans, caloric restriction over a few
years have produced significant reductions in body weight,
blood pressure, blood cholesterol, and blood sugar, as well as
reduced the development of atherosclerosis and ameliorated
the decline in diastolic function.116–118
Pertinent to this review, caloric restriction in animals has
been shown to modulate the aging-related physiological
processes in kidney. Caloric restriction attenuated the
increased aging-related susceptibility of rat kidney to
ischemic injury, perhaps by molecular alterations such as
the attenuation of aging-related changes in expression of
genes such as claudin-7, kidney injury molecule-1, and
matrix metalloproteinase-7.119 In another study, investigators
studied aging-related structural changes in the kidneys of
FischerBrown Norway rats fed with a 40% calorie-
restriction diet initiated in middle-aged rats, before the onset
of significant aging-related renal changes. Compared with
age-matched rats on a regular diet, the rats fed with a calorie-
restricted diet showed reduced glomerulosclerosis, tubular
atrophy, interstitial fibrosis, vascular wall thickening, and the
expression of cytochrome c oxidase-deficient tubular epithe-
lial cells.120 Similarly, caloric restriction prevented or delayed
the development of structural (glomerulosclerosis, tubuloin-
terstitial damage) and functional changes, as well as
morbidity and mortality associated with chronic nephro-
pathy in ad libitum-overfed Sprague–Dawley rats.121 In 24-
month-old F344BN rats, caloric restriction reduced the
aging-related proteinuria, extracellular matrix accumulation,
and the renal expression of connective tissue growth factor,
vascular endothelial growth factor, and plasminogen activa-
tor inhibitor-1. As these changes were associated with a
decline in the renal expression of sterol regulatory element
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binding proteins, SREBP-1 and SREBP-2, and a decline in
renal triglyceride and cholesterol content, the authors
suggested that caloric restriction affects aging-related renal
physiology, in part, by altering renal SREBP expression and
renal lipid accumulation.122 Caloric restriction also attenuates
the aging-related increase in plasma levels of F2-isoprostanes,
markers of oxidative stress that have been implicated in aging-
related renal dysfunctions.123 Similarly, the markers of
oxidative stress, malondialdehyde, and 4-hydroxynonenal were
markedly lower in aged rats fed with calorie-restricted diets
compared with the aged rats fed ad libitum. In addition, the
apoptosis was suppressed in aged rats on calorie-restricted
diets, as shown by increased levels of Bcl-2 and procaspase 3
and decreased levels of Bax and cleaved caspase 3.124
AGING AND RENAL TRANSPLANTATION
Given the prevalence of end-stage kidney disease in the
elderly, it is not surprising that among the more than 300,000
US patients currently on dialysis, the prevalence rates are the
highest among the patients in their seventh and eighth
decades of life.7 Consequently, the number of patients with
end-stage kidney disease who could potentially benefit from
renal transplantation is greatest in the older age groups.
Given the perpetual shortage of and the long waiting list for
donor kidneys, kidney transplantation in the elderly with
end-stage renal failure raises ethical questions related to the
concept of net benefit. Should a donor kidney be trans-
planted to an elderly patient with comorbidities and an
average life expectancy of 10–15 years over a younger patient?
Studies have clearly shown that the elderly patients with end-
stage renal failure do benefit from kidney transplanta-
tion.7,125,126 In fact, the relative risk of renal graft failure,
adjusted for comorbidities, is statistically similar for renal
transplant recipients older than 65 years and their younger
counterparts.127,128 The most common cause of graft loss in
the elderly transplant recipient is the comorbidities-related
demise of the patient. Thus, careful screening of elderly
patients for comorbidities such as cancer, cardiovascular
disease, peripheral vascular disease, diabetes mellitus, and
chronic obstructive pulmonary disease may help minimize
early post-transplant morbidity and mortality.7 There is
currently no age limit for access to renal transplantation in
the US,129 and the patients older than 65 years comprise 13%
of all recipients of cadaveric donor kidneys.7 Another related
medicosocial ramification of the aging population is that the
average age of the cadaveric kidney donors is increasing,
which is contributed also by the decreasing mortality in the
young. The ‘expanded criteria donor’ kidneys allow for the
use of kidneys from donors over the age of 60 years or donors
over the age of 50 years with two comorbidities including
hypertension, death from cerebrovascular accident, or
terminal serum creatinine levels greater than 1.5 mg/100 ml
(see ref. 130). Accordingly, there are two renal-transplant lists
in the US: one for standard criteria and the other for
expanded criteria donors, with the latter list recommended
for older patients, patients with diabetes as the primary cause
for renal failure, and patients with difficult vascular access. A
comparable Eurotransplant Senior Program in Europe allows
for local allocation of kidneys from donors over 65 years of
age to recipients over the age for 65 years (‘old for old’ kidney
allocation). Expanded-spectrum donor kidneys now com-
prise 17% of the cadaveric donor transplants in the US.131
However, older renal allografts do have an increased risk of
graft failure, mainly because of aging-related decline in renal
function, predisposition to ischemia and drug toxicity,
reduced capacity for repair, and a higher degree of
immunogenecity.132,133 Yet, most allograft failures in older
recipients are due to unrelated death with a functioning
allograft, and therefore ‘old for old’ kidney allocation is a
sensible approach. Another strategy for obtaining maximal
benefit from expanded criteria donor kidneys is the use of
dual renal transplants that allows for the use of two marginal
kidneys into one recipient.134,135 Pre-implantation histologi-
cal evaluation of the expanded criteria donor kidney further
optimizes their use. In a histological scoring schema, with 0
representing no lesions and 12 representing severe changes in
the renal parenchyma, kidneys with a score of 3 or less should
have enough viable nephrons for single-kidney transplants,
those with scores 4–6 should have enough viable nephrons for
dual-kidney transplants, and kidneys with scores higher than
6 are unsuitable for transplantation.136,137
FUTURE DIRECTIONS
Although substantial progress has been made in the under-
standing of the renal aging process and the associated decline
in renal function, many questions remain unanswered and
await future investigation. Improved understanding of renal
aging may help to optimize management of renal allografts
obtained from older donors. For instance, it has been
suggested that the early occurrence of critical telomere
shortening and replicative senescence may contribute to the
pathogenesis of chronic allograft nephropathy in older
allografts.138 Future studies should seek distinction between
the decline in renal function and alteration in renal structure
because of aging-associated diseases such as hypertension and
diabetes mellitus and that solely because of aging. This
information would be critical in promoting health and
formulating individualized care for the elderly populations.
Further studies also need to further define the role of diet and
caloric restriction on the process of renal aging.
Another area of potential study is the role of gender in
renal aging. It has been increasingly recognized that gender
plays a vital role in structural changes and progression of
renal impairment associated with senescence. Earlier, we
mentioned the results of a study that showed that the
reduction in RPF induced by intravenous administration of
the NOS inhibitor, L-NAME, increased markedly with aging
in men but not women.26 It has also been shown in male
animals that much of the aging-related renal damage,
including vascular changes, may be related to androgen
production, and that castration can limit the progression of
aging-related changes.139–141 Furthermore, in some animal
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models, therapy with estrogen-related compounds can
protect males against some of these changes.142 Further
studies are required to investigate the cellular mechanisms
that may serve as potential therapeutic targets for the
prevention of age-associated renal disease.
Widely considered as one of the most important and
complex biological problems of the twenty-first century, aging
is essentially a process of degradation of systems.143 Currently, a
large majority of the studies addressing the molecular pathways
involved in aging are focusing on a single or a limited number
of pathways. However, to better understand the complex
mechanisms of aging and its associated renal dysfunctions, an
intensely multidisciplinary approach known as ‘systems
biology’ would be needed to ensure that the elderly remains
healthy and productive in the society.143
DISCLOSURE
All the authors declared no competing interests.
REFERENCES
1. CDC. The State of Aging and Health in America 2007 Report. In (vol
2007), Centers for Disease Control and Prevention, 2007.
2. Csiszar A, Toth J, Peti-Peterdi J et al. The aging kidney: role of
endothelial oxidative stress and inflammation. Acta Physiologica
Hungarica 2007; 94: 107–115.
3. Zhen JH, Li L, Zhou XJ. The aging kidney and associated renal diseases.
In: Li LS, Liu ZH (eds). Nephrology in China (In press).
4. Buemi M, Nostro L, Aloisi C et al. Kidney aging: from phenotype to
genetics. Rejuvenation Res 2005; 8: 101–109.
5. USRDS. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney
Disease and End-Stage Renal Disease in the United States. In (vol 2007),
National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases, Bethesda, MD, 2007.
6. Silva FG. The aging kidney: a review—part II. Int Urol Nephrol 2005; 37:
419–432.
7. Silva FG. The aging kidney: a review—part I. Int Urol Nephrol 2005; 37:
185–205.
8. Zhou XJ, Saxena R, Liu ZH et al. Renal senescence in 2008: progress and
challenges. Int Urol Nephrol [E-pub ahead of print 27 June 2008].
9. Morrissey PE, Yango AF. Renal transplantation: older recipients and
donors. Clin Geriatr Med 2006; 22: 687–707.
10. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of
decline in renal function with age. J Am Geriatr Soc 1985; 33: 278–285.
11. Sesso R, Prado F, Vicioso B et al. Prospective study of progression of
kidney dysfunction in community-dwelling older adults. Nephrology
2008; 13: 99–103.
12. Feinfeld DA, Guzik H, Carvounis CP et al. Sequential changes in renal
function tests in the old: results from the Bronx Longitudinal Aging
Study. J Am Geriatr Soc 1995; 43: 412–414.
13. Feinfeld DA, Keller S, Somer B et al. Serum creatinine and blood urea
nitrogen over a six-year period in the very old. Creatinine and BUN in
the very old. Geriatr Nephrol Urol 1998; 8: 131–135.
14. Kimmel PL, Lew SQ, Bosch JP. Nutrition, ageing and GFR: is age-
associated decline inevitable? Nephrol Dial Transplant 1996; 11(Suppl 9):
85–88.
15. Musch W, Verfaillie L, Decaux G. Age-related increase in plasma urea
level and decrease in fractional urea excretion: clinical application in the
syndrome of inappropriate secretion of antidiuretic hormone. Clin J Am
Soc Nephrol 2006; 1: 909–914.
16. Fliser D, Bischoff I, Hanses A et al. Renal handling of drugs in the healthy
elderly. Creatinine clearance underestimates renal function and
pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol
1999; 55: 205–211.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum
creatinine. Nephron 1976; 16: 31–41.
18. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate
glomerular filtration rate from serum creatinine: a new prediction
equation. Modification of Diet in Renal Disease Study Group. Ann Intern
Med 1999; 130: 461–470.
19. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice
guidelines for chronic kidney disease: evaluation, classification, and
stratification. Ann Intern Med 2003; 139: 137–147.
20. Wieczorowska-Tobis K, Niemir ZI, Guzik P et al. Difference in estimated
GFR with two different formulas in elderly individuals. Int Urol Nephrol
2006; 38: 381–385.
21. Berman N, Hostetter TH. Comparing the Cockcroft-Gault and MDRD
equations for calculation of GFR and drug doses in the elderly. Nat Clin
Practice 2007; 3: 644–645.
22. Gill J, Malyuk R, Djurdjev O et al. Use of GFR equations to adjust drug
doses in an elderly multi-ethnic group—a cautionary tale. Nephrol Dial
Transplant 2007; 22: 2894–2899.
23. Ognibene A, Mannucci E, Caldini A et al. Cystatin C reference values and
aging. Clin Biochem 2006; 39: 658–661.
24. Fuiano G, Sund S, Mazza G et al. Renal hemodynamic response to
maximal vasodilating stimulus in healthy older subjects. Kidney Int 2001;
59: 1052–1058.
25. Esposito C, Plati A, Mazzullo T et al. Renal function and functional
reserve in healthy elderly individuals. J Nephrol 2007; 20: 617–625.
26. Ahmed SB, Fisher ND, Hollenberg NK. Gender and the renal nitric oxide
synthase system in healthy humans. Clin J Am Soc Nephrol 2007; 2:
926–931.
27. Kielstein JT, Bode-Boger SM, Frolich JC et al. Asymmetric
dimethylarginine, blood pressure, and renal perfusion in elderly
subjects. Circulation 2003; 107: 1891–1895.
28. Kielstein JT, Bode-Boger SM, Haller H et al. Functional changes in the
ageing kidney: is there a role for asymmetric dimethylarginine? Nephrol
Dial Transplant 2003; 18: 1245–1248.
29. Epstein M, Hollenberg NK. Age as a determinant of renal sodium
conservation in normal man. J Lab Clin Med 1976; 87: 411–417.
30. Fliser D, Franek E, Joest M et al. Renal function in the elderly: impact of
hypertension and cardiac function. Kidney Int 1997; 51: 1196–1204.
31. Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly: drugs
exacerbate impaired potassium homeostasis. J Gen Intern Med 1997; 12:
646–656.
32. Rowe JW, Shock NW, DeFronzo RA. The influence of age on the renal
response to water deprivation in man. Nephron 1976; 17: 270–278.
33. Sands JM. Urine-concentrating ability in the aging kidney. Sci Aging
Knowledge Environ 2003; 2003: PE15.
34. Kirkland JL, Lye M, Levy DW et al. Patterns of urine flow and electrolyte
excretion in healthy elderly people. BMJ (Clinical Res Ed) 1983; 287:
1665–1667.
35. Faull CM, Holmes C, Baylis PH. Water balance in elderly people: is there a
deficiency of vasopressin? Age and Ageing 1993; 22: 114–120.
36. ElDesoky ES. Pharmacokinetic–pharmacodynamic crisis in the elderly.
Am J Therapeut 2007; 14: 488–498.
37. Ble A, Fink JC, Woodman RC et al. Renal function, erythropoietin, and
anemia of older persons: the InCHIANTI study. Arch Int Med 2005; 165:
2222–2227.
38. Eisenstaedt R, Penninx BW, Woodman RC. Anemia in the elderly: current
understanding and emerging concepts. Blood Reviews 2006; 20:
213–226.
39. Ershler WB, Sheng S, McKelvey J et al. Serum erythropoietin and aging:
a longitudinal analysis. J Am Geriatr Soc 2005; 53: 1360–1365.
40. Carpenter MA, Kendall RG, O’Brien AE et al. Reduced erythropoietin
response to anaemia in elderly patients with normocytic anaemia.
Eur J Haematol 1992; 49: 119–121.
41. Ferrucci L, Guralnik JM, Bandinelli S et al. Unexplained anaemia in
older persons is characterised by low erythropoietin and low levels of
pro-inflammatory markers. Brit J Haematol 2007; 136: 849–855.
42. Kario K, Matsuo T, Kodama K et al. Reduced erythropoietin secretion in
senile anemia. Am J Hematol 1992; 41: 252–257.
43. Gallagher JC, Rapuri P, Smith L. Falls are associated with decreased renal
function and insufficient calcitriol production by the kidney. J Ster
Biochem Mol Biol 2007; 103: 610–613.
44. Dukas L, Schacht E, Stahelin HB. In elderly men and women treated for
osteoporosis a low creatinine clearance ofo65 ml/min is a risk factor for
falls and fractures. Osteoporos Int 2005; 16: 1683–1690.
45. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress
and potential. Endocrine Rev 1998; 19: 608–624.
46. Massry SG, Fadda GZ, Zhou XJ et al. Impaired insulin secretion of aging:
role of renal failure and hyperparathyroidism. Kidney Int 1991; 40:
662–667.
47. Basu R, Breda E, Oberg AL et al. Mechanisms of the age-associated
deterioration in glucose tolerance: contribution of alterations in insulin
secretion, action, and clearance. Diabetes 2003; 52: 1738–1748.
718 Kidney International (2008) 74, 710–720
r e v i e w XJ Zhou et al.: The aging kidney
48. Kosch M, Barenbrock M, Kisters K et al. Relationship between muscle
sympathetic nerve activity and large artery mechanical vessel wall
properties in renal transplant patients. J Hypertens 2002; 20: 501–508.
49. Grassi G, Calhoun DA. Sympathetic–vascular interactions: further
evidence in kidney transplantation. J Hypertens 2002; 20: 379–381.
50. Zhou XJ, Laszik ZG, Silva FG. Anatomical changes in the aging kidney.
In: Macias-Nunez JF, Cameron JS, Oreopoulos DG (eds). The Aging Kidney
in Health and Disease. Springer, New York, 2007, pp 39–54.
51. Takazakura E, Sawabu N, Handa A et al. Intrarenal vascular changes with
age and disease. Kidney Int 1972; 2: 224–230.
52. Tracy RE, Ishii T. What is ‘nephrosclerosis’? lessons from the US, Japan,
and Mexico. Nephrol Dial Transplant 2000; 15: 1357–1366.
53. Tracy RE, Malcom GT, Oalmann MC et al. Renal microvascular features of
hypertension in Japan, Guatemala, and the United States. Arch Pathol
Lab Med 1992; 116: 50–55.
54. Tracy RE, Newman III WP, Wattigney WA et al. Histologic features of
atherosclerosis and hypertension from autopsies of young individuals in
a defined geographic population: the Bogalusa Heart Study.
Atherosclerosis 1995; 116: 163–179.
55. Tracy RE, Parra D, Eisaguirre W et al. Influence of arteriolar hyalinization
on arterial intimal fibroplasia in the renal cortex of subjects in the United
States, Peru, and Bolivia, applicable also to other populations. Am J
Hypertens 2002; 15: 1064–1073.
56. Hughson MD, Douglas-Denton R, Bertram JF et al. Hypertension,
glomerular number, and birth weight in African Americans and
white subjects in the southeastern United States. Kidney Int 2006; 69:
671–678.
57. Newbold KM, Sandison A, Howie AJ. Comparison of size of
juxtamedullary and outer cortical glomeruli in normal adult kidney.
Virchows Archiv 1992; 420: 127–129.
58. Nyengaard JR, Bendtsen TF. Glomerular number and size in relation to
age, kidney weight, and body surface in normal man. Anat Rec 1992;
232: 194–201.
59. Kasiske BL. Relationship between vascular disease and age-associated
changes in the human kidney. Kidney Int 1987; 31: 1153–1159.
60. Kaplan C, Pasternack B, Shah H et al. Age-related incidence of sclerotic
glomeruli in human kidneys. Am J Pathol 1975; 80: 227–234.
61. Smith SM, Hoy WE, Cobb L. Low incidence of glomerulosclerosis in
normal kidneys. Arch Pathol Lab Med 1989; 113: 1253–1255.
62. Nadasdy T, Laszik Z, Blick KE et al. Tubular atrophy in the end-stage
kidney: a lectin and immunohistochemical study. Human Pathol 1994;
25: 22–28.
63. Baert L, Steg A. Is the diverticulum of the distal and collecting tubules a
preliminary stage of the simple cyst in the adult? J Urol 1977; 118:
707–710.
64. Tada S, Yamagishi J, Kobayashi H et al. The incidence of simple renal cyst
by computed tomography. Clin Radiol 1983; 34: 437–439.
65. Brenner BM. Hemodynamically mediated glomerular injury and the
progressive nature of kidney disease. Kidney Int 1983; 23: 647–655.
66. Hill GS, Heudes D, Bariety J. Morphometric study of arterioles and
glomeruli in the aging kidney suggests focal loss of autoregulation.
Kidney Int 2003; 63: 1027–1036.
67. Samuel T, Hoy WE, Douglas-Denton R et al. Determinants of glomerular
volume in different cortical zones of the human kidney. J Am Soc
Nephrol 2005; 16: 3102–3109.
68. Tanaka T, Kato H, Kojima I et al. Hypoxia and expression of hypoxia-
inducible factor in the aging kidney. J Gerontol 2006; 61: 795–805.
69. Gagliano N, Arosio B, Santambrogio D et al. Age-dependent expression
of fibrosis-related genes and collagen deposition in rat kidney cortex.
J Gerontol 2000; 55: B365–B372.
70. Martin JE, Sheaff MT. Renal ageing. J Pathol 2007; 211: 198–205.
71. Lu C, He JC, Cai W et al. Advanced glycation endproduct (AGE) receptor
1 is a negative regulator of the inflammatory response to AGE in
mesangial cells. Proc Natl Acad Sci USA 2004; 101: 11767–11772.
72. Zhang X, Chen X, Hong Q et al. TIMP-1 promotes age-related renal
fibrosis through upregulating ICAM-1 in human TIMP-1 transgenic mice.
J Gerontol 2006; 61: 1130–1143.
73. Ruiz-Torres MP, Bosch RJ, O’Valle F et al. Age-related increase in
expression of TGF-beta1 in the rat kidney: relationship to morphologic
changes. J Am Soc Nephrol 1998; 9: 782–791.
74. Nichols WW, O’Rourke MF. McDonald’s Blood Flow in Arteries:
Theoretical, Experimental and Clinical Principles, 5th edn. Hodder Arnold,
London, 2005.
75. Boutouyrie P, Laurent S, Benetos A et al. Opposing effects of ageing on
distal and proximal large arteries in hypertensives. J Hypertens Suppl
1992; 10: S87–S91.
76. Laurent S, Cockcroft J, Van Bortel L et al. Expert consensus document
on arterial stiffness: methodological issues and clinical applications.
Eur Heart J 2006; 27: 2588–2605.
77. Bakris G. Proteinuria: a link to understanding changes in vascular
compliance? Hypertension 2005; 46: 473–474.
78. Verhave JC, Fesler P, du Cailar G et al. Elevated pulse pressure is
associated with low renal function in elderly patients with isolated
systolic hypertension. Hypertension 2005; 45: 586–591.
79. Lea J, Greene T, Hebert L et al. The relationship between magnitude of
proteinuria reduction and risk of end-stage renal disease: results of the
African American study of kidney disease and hypertension. Arch Int
Med 2005; 165: 947–953.
80. O’Rourke MF. Arterial aging: pathophysiological principles. Vasc Med
2007; 12: 329–341.
81. Edwards MS, Wilson DB, Craven TE et al. Associations between retinal
microvascular abnormalities and declining renal function in the elderly
population: the Cardiovascular Health Study. Am J Kidney Dis 2005; 46:
214–224.
82. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates
to reduction in cardiovascular events in hypertensive patients: losartan
intervention for endpoint reduction in hypertension study. Hypertension
2005; 45: 198–202.
83. Sarnak MJ, Greene T, Wang X et al. The effect of a lower target blood
pressure on the progression of kidney disease: long-term follow-up of
the modification of diet in renal disease study. Ann Intern Med 2005;
142: 342–351.
84. Williams B, Lacy PS, Thom SM et al. Differential impact of blood
pressure-lowering drugs on central aortic pressure and clinical
outcomes: principal results of the Conduit Artery Function Evaluation
(CAFE) study. Circulation 2006; 113: 1213–1225.
85. Johnson FB, Sinclair DA, Guarente L. Molecular biology of aging.
Cell 1999; 96: 291–302.
86. Melk A. Senescence of renal cells: molecular basis and clinical
implications. Nephrol Dial Transplant 2003; 18: 2474–2478.
87. Jiang H, Ju Z, Rudolph KL. Telomere shortening and ageing. Z Gerontol
Geriatr 2007; 40: 314–324.
88. Melk A, Ramassar V, Helms LM et al. Telomere shortening in kidneys
with age. J Am Soc Nephrol 2000; 11: 444–453.
89. Zou AP, Cowley Jr AW. Reactive oxygen species and molecular
regulation of renal oxygenation. Acta Physiol Scand 2003; 179: 233–241.
90. Frenkel-Denkberg G, Gershon D, Levy AP. The function of hypoxia-
inducible factor 1 (HIF-1) is impaired in senescent mice. FEBS Lett 1999;
462: 341–344.
91. Reckelhoff JF, Kanji V, Racusen LC et al. Vitamin E ameliorates enhanced
renal lipid peroxidation and accumulation of F2-isoprostanes in aging
kidneys. Am J Physiol 1998; 274: R767–R774.
92. Houben JM, Moonen HJ, van Schooten FJ et al. Telomere length
assessment: biomarker of chronic oxidative stress? Free Radic Biol Med
2008; 44: 235–246.
93. Verbeke P, Perichon M, Friguet B et al. Inhibition of nitric oxide synthase
activity by early and advanced glycation end products in cultured rabbit
proximal tubular epithelial cells. Biochim Biophys Acta 2000; 1502:
481–494.
94. Thomas SE, Anderson S, Gordon KL et al. Tubulointerstitial disease in
aging: evidence for underlying peritubular capillary damage, a potential
role for renal ischemia. J Am Soc Nephrol 1998; 9: 231–242.
95. Erdely A, Greenfeld Z, Wagner L et al. Sexual dimorphism in the aging
kidney: effects on injury and nitric oxide system. Kidney Int 2003; 63:
1021–1026.
96. Rosenfeld CR, Chen C, Roy T et al. Estrogen selectively up-regulates
eNOS and nNOS in reproductive arteries by transcriptional mechanisms.
J Soc Gynecol Investig 2003; 10: 205–215.
97. Basso N, Paglia N, Stella I et al. Protective effect of the inhibition of the
renin–angiotensin system on aging. Regul Pept 2005; 128: 247–252.
98. de Cavanagh EM, Piotrkowski B, Basso N et al. Enalapril and losartan
attenuate mitochondrial dysfunction in aged rats. FASEB J 2003; 17:
1096–1098.
99. Zhou XJ, Vaziri ND, Zhang J et al. Association of renal injury with nitric
oxide deficiency in aged SHR: prevention by hypertension control with
AT1 blockade. Kidney Int 2002; 62: 914–921.
100. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho
gene leads to a syndrome resembling ageing. Nature 1997; 390: 45–51.
101. Kurosu H, Yamamoto M, Clark JD et al. Suppression of aging in mice by
the hormone Klotho. Science 2005; 309: 1829–1833.
102. Kuro-o M. Klotho as a regulator of oxidative stress and senescence.
Biol Chem 2008; 389: 233–241.
Kidney International (2008) 74, 710–720 719
XJ Zhou et al.: The aging kidney r e v i e w
103. Mitobe M, Yoshida T, Sugiura H et al. Oxidative stress decreases klotho
expression in a mouse kidney cell line. Nephron 2005; 101: e67–e74.
104. Saito K, Ishizaka N, Mitani H et al. Iron chelation and a free radical
scavenger suppress angiotensin II-induced downregulation of klotho, an
anti-aging gene, in rat. FEBS Lett 2003; 551: 58–62.
105. Razzaque MS, Lanske B. The emerging role of the fibroblast growth
factor-23-klotho axis in renal regulation of phosphate homeostasis.
J Endocrinol 2007; 194: 1–10.
106. Mensenkamp AR, Hoenderop JG, Bindels RJ. Recent advances in renal
tubular calcium reabsorption. Curr Opin Nephrol Hypertens 2006; 15:
524–529.
107. Torres PU, Prie D, Molina-Bletry V et al. Klotho: an antiaging protein
involved in mineral and vitamin D metabolism. Kidney Int 2007; 71:
730–737.
108. Kawano K, Ogata N, Chiano M et al. Klotho gene polymorphisms
associated with bone density of aged postmenopausal women.
J Bone Miner Res 2002; 17: 1744–1751.
109. Yamada Y, Ando F, Niino N et al. Association of polymorphisms of the
androgen receptor and klotho genes with bone mineral density in
Japanese women. J Mol Med 2005; 83: 50–57.
110. Arking DE, Krebsova A, Macek Sr M et al. Association of human aging
with a functional variant of klotho. Proc Natl Acad Sci USA 2002; 99:
856–861.
111. Ichikawa S, Imel EA, Kreiter ML et al. A homozygous missense mutation
in human KLOTHO causes severe tumoral calcinosis. J Clin Investig 2007;
117: 2684–2691.
112. Melk A, Mansfield ES, Hsieh SC et al. Transcriptional analysis of the
molecular basis of human kidney aging using cDNA microarray profiling.
Kidney Int 2005; 68: 2667–2679.
113. McCay CM, Crowell MF, Maynard LA. The effect of retarded growth upon
the length of life span and upon the ultimate body size. 1935. Nutrition
1989; 5: 155–171; discussion 172.
114. Simms HS, Berg BN. Longevity in relation to lesion onset. Geriatrics 1962;
17: 235–242.
115. Yu BP. How diet influences the aging process of the rat. Proc Soc Exp Biol
Med Soc Exp Biol Med 1994; 205: 97–105.
116. Fontana L, Meyer TE, Klein S et al. Long-term calorie restriction is highly
effective in reducing the risk for atherosclerosis in humans. Proc Natl
Acad Sci USA 2004; 101: 6659–6663.
117. Meyer TE, Kovacs SJ, Ehsani AA et al. Long-term caloric restriction
ameliorates the decline in diastolic function in humans. J Am Coll Cardiol
2006; 47: 398–402.
118. Walford RL, Mock D, Verdery R et al. Calorie restriction in biosphere 2:
alterations in physiologic, hematologic, hormonal, and biochemical
parameters in humans restricted for a 2-year period. J Gerontol 2002; 57:
B211–B224.
119. Chen G, Bridenbaugh EA, Akintola AD et al. Increased susceptibility of
aging kidney to ischemic injury: identification of candidate genes
changed during aging, but corrected by caloric restriction. Am J Physiol
2007; 293: F1272–F1281.
120. McKiernan SH, Tuen VC, Baldwin K et al. Adult-onset calorie restriction
delays the accumulation of mitochondrial enzyme abnormalities in
aging rat kidney tubular epithelial cells. Am J Physiol 2007; 292:
F1751–F1760.
121. Keenan KP, Coleman JB, McCoy CL et al. Chronic nephropathy in ad
libitum overfed Sprague–Dawley rats and its early attenuation by
increasing degrees of dietary (caloric) restriction to control growth.
Toxicol Pathol 2000; 28: 788–798.
122. Jiang T, Liebman SE, Lucia MS et al. Calorie restriction modulates renal
expression of sterol regulatory element binding proteins, lipid
accumulation, and age-related renal disease. J Am Soc Nephrol 2005; 16:
2385–2394.
123. Ward WF, Qi W, Van Remmen H et al. Effects of age and caloric
restriction on lipid peroxidation: measurement of oxidative stress by
F2-isoprostane levels. J Gerontol 2005; 60: 847–851.
124. Lee JH, Jung KJ, Kim JW et al. Suppression of apoptosis by calorie
restriction in aged kidney. Exp Gerontol 2004; 39: 1361–1368.
125. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all
patients on dialysis, patients on dialysis awaiting transplantation, and
recipients of a first cadaveric transplant. N Engl J Med 1999; 341:
1725–1730.
126. Macrae J, Friedman AL, Friedman EA et al. Live and deceased donor
kidney transplantation in patients aged 75 years and older in the United
States. Int Urol Nephrol 2005; 37: 641–648.
127. Fabrizii V, Horl WH. Renal transplantation in the elderly. Curr Opin Urol
2001; 11: 159–163.
128. Oniscu GC, Brown H, Forsythe JL. How old is old for transplantation?
Am J Transplant 2004; 4: 2067–2074.
129. Rao PS, Merion RM, Ashby VB et al. Renal transplantation in elderly
patients older than 70 years of age: results from the Scientific Registry of
Transplant Recipients. Transplantation 2007; 83: 1069–1074.
130. Metzger RA, Delmonico FL, Feng S et al. Expanded criteria donors for
kidney transplantation. Am J Transplant 2003; 3(Suppl 4): 114–125.
131. Schold JD, Kaplan B, Baliga RS et al. The broad spectrum of quality in
deceased donor kidneys. Am J Transplant 2005; 5: 757–765.
132. Nyberg SL, Baskin-Bey ES, Kremers W et al. Improving the prediction of
donor kidney quality: deceased donor score and resistive indices.
Transplantation 2005; 80: 925–929.
133. Bunnapradist S, Daswani A, Takemoto SK. Graft survival following
living-donor renal transplantation: a comparison of tacrolimus and
cyclosporine microemulsion with mycophenolate mofetil and steroids.
Transplantation 2003; 76: 10–15.
134. Lu AD, Carter JT, Weinstein RJ et al. Outcome in recipients of dual kidney
transplants: an analysis of the dual registry patients. Transplantation
2000; 69: 281–285.
135. Tan JC, Alfrey EJ, Dafoe DC et al. Dual-kidney transplantation with
organs from expanded criteria donors: a long-term follow-up.
Transplantation 2004; 78: 692–696.
136. Remuzzi G, Cravedi P, Perna A et al. Long-term outcome of renal
transplantation from older donors. N Engl J Med 2006; 354: 343–352.
137. Ruggenenti P, Perico N, Remuzzi G. Ways to boost kidney transplant
viability: a real need for the best use of older donors. Am J Transplant
2006; 6: 2543–2547.
138. Ferlicot S, Durrbach A, Ba N et al. The role of replicative senescence in
chronic allograft nephropathy. Hum Pathol 2003; 34: 924–928.
139. Baylis C. Age-dependent glomerular damage in the rat. Dissociation
between glomerular injury and both glomerular hypertension and
hypertrophy. Male gender as a primary risk factor. J Clin Investig 1994;
94: 1823–1829.
140. Tanaka A, Kyokuwa M, Mori T et al. Acceleration of renal dysfunction
with ageing by the use of androgen in Wistar/Tw rats. In Vivo 1995; 9:
495–502.
141. Francois V, Heudes D, Bariety J et al. Glomerular capillary network of
cortical nephrons is reduced in male but not in female aging rats. Mech
Ageing Dev 1996; 91: 11–22.
142. Maric C, Sandberg K, Hinojosa-Laborde C. Glomerulosclerosis and
tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the
aging Dahl salt sensitive rat. J Am Soc Nephrol 2004; 15: 1546–1556.
143. Kirkwood TB. A systematic look at an old problem. Nature 2008; 451:
644–647.
720 Kidney International (2008) 74, 710–720
r e v i e w XJ Zhou et al.: The aging kidney
